Large Ocular Therapeutix (OCUL) share gift to spouse disclosed

Rhea-AI Filing Summary

Ocular Therapeutix director Pravin Dugel reported a bona fide gift of 394,696 shares of Common Stock on April 9, 2026, transferred to his spouse for no consideration. The transfer was recorded as a gift disposition and reflects an internal family reallocation rather than a market sale.

After this transaction, Dugel continues to hold 2,618,326 shares directly. He also has indirect ownership of 394,696 shares held by his spouse and 300,115 shares held by the Pravin Dugel 2024 Irrevocable Trust, indicating a substantial remaining stake in the company.

Insider Trade Summary

789,392 shares gifted

Mixed 3 txns

Insider Dugel Pravin

Role See Remarks

Type	Security	Shares	Price	Value
Gift	Common Stock	394,696	$0.00	--
Gift	Common Stock	394,696	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,618,326 shares (Direct); Common Stock — 394,696 shares (Indirect, By spouse)

Footnotes (1)

1. [object Object]

Key Figures

Gifted shares: 394,696 shares Direct holdings after transaction: 2,618,326 shares Spouse indirect holdings: 394,696 shares +1 more

4 metrics

Gifted shares 394,696 shares Bona fide gift of Common Stock on April 9, 2026

Direct holdings after transaction 2,618,326 shares Direct Common Stock held by Pravin Dugel after reported gift

Spouse indirect holdings 394,696 shares Common Stock held indirectly through spouse after transfer

Trust indirect holdings 300,115 shares Common Stock held by Pravin Dugel 2024 Irrevocable Trust

Key Terms

bona fide gift, indirect ownership, Irrevocable Trust

3 terms

bona fide gift financial

"transaction_code_description: "Bona fide gift" for the Common Stock transfer"

indirect ownership financial

"ownership_code "I" with nature_of_ownership "By spouse" and trust holdings"

Irrevocable Trust financial

"nature_of_ownership: "By Pravin Dugel 2024 Irrevocable Trust""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugel Pravin

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/09/2026		G(1)		394,696	D	$0	2,618,326	D
Common Stock	04/09/2026		G(1)		394,696	A	$0	394,696	I	By spouse
Common Stock								300,115	I	By Pravin Dugel 2024 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 9, 2026, the reporting person transferred 394,696 shares to his spouse for no consideration.

Remarks:

Executive Chairman, President and CEO

	/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OCUL director Pravin Dugel report?

Pravin Dugel reported a bona fide gift of 394,696 Ocular Therapeutix (OCUL) Common Stock shares. The shares were transferred to his spouse for no consideration, meaning no cash was received and the move reflects a personal estate or family allocation rather than a market trade.

Did Pravin Dugel sell any OCUL shares in the reported Form 4?

No open-market sales were reported; the Form 4 shows a bona fide gift of 394,696 shares to his spouse. The transaction was executed at zero dollars per share, indicating it was a non-cash transfer within the family, not a sale into the market.

How many OCUL shares does Pravin Dugel hold after the gift?

Following the gift, Pravin Dugel directly holds 2,618,326 OCUL Common Stock shares. In addition, he has indirect ownership of 394,696 shares held by his spouse and 300,115 shares held by the Pravin Dugel 2024 Irrevocable Trust, according to the Form 4 disclosure.

How is the OCUL share transfer to Pravin Dugel’s spouse characterized?

The transfer of 394,696 OCUL shares to Pravin Dugel’s spouse is characterized as a bona fide gift. The filing notes the shares were transferred for no consideration, so it is treated as a personal transfer rather than a sale, with no transaction price per share reported.

What indirect OCUL holdings related to Pravin Dugel are reported?

Indirect holdings include 394,696 OCUL shares held by his spouse and 300,115 OCUL shares held by the Pravin Dugel 2024 Irrevocable Trust. These positions are reported as indirect ownership on the Form 4, supplementing Dugel’s separate direct holdings in Ocular Therapeutix.